henry md semaglutide for Weight Loss Online Weight Management - Henry

For actuaries, that shift matters more because obesity is a major driver of long-term health costs and mortality risk across insured populations

Obesity SURMOUNT-1 Trial In adults with obesity (without diabetes): Tirzepatide (15 mg) : 20.9% average body weight reduction over 72 weeks Semaglutide (2.4 mg) (based on STEP trials): ~14.9% average reduction STEP 5 Long-Term Results Semaglutide also demonstrated durable effects: At 104 weeks, patients maintained ~15% weight loss on semaglutide 2.4 mg (STEP 5) SELECT Trial Cardiovascular Benefit Semaglutide significantly reduced major adverse cardiovascular events by 20% in people with obesity and pre-existing heart diseaseindicating benefit beyond weight loss

Additionally, proteolytic degradation is a major challenge in peptide-based therapeutics, as it results in short half-life, low bioavailability, rapid clearance, and ultimately reduced therapeutic efficacy

This pales in comparison to medications approved to treat other diseases, Hendershot said